



# SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

**Ref: SPL/CORP-SEC/2020-21/BSE/1246**

**Dated: 14.09.2020**

**To,**

Bombay Stock Exchange Ltd,  
Phirojshah Jeejobhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

**Sub: Outcome of the Board Meeting for the FY 2020-21 held on Monday, 14th September 2020 with Scrip Code 524703.**

A Meeting of the Board of Directors of the Company duly convened on Monday, 14th September 2020 at 4:30 p.m. and Concluded at 5.15 p.m. at the Corporate Office of the Company at Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai 400071 inter alia, discussed the following business:-

- (a) It has approved Unaudited Financial Results for the Quarter ended 30<sup>th</sup> June 2020 along with Limited Review Report.

You are requested to kindly take the same on record.

Yours Faithfully,

**For Sandu Pharmaceuticals Limited**

**Company Secretary**



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587



Sandu Pharmaceuticals Ltd				
STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/06/20				
				(Rs In Lakhs)
Particulars	Qtr Ending June 2020 (Un audited)	Qtr Ending March 2020 (Audited)	Qtr Ending June 2019 (Un Audited)	Year Ended March 2020 (Audited)
I Revenue From Operations	1,166.97	1,101.67	1,234.53	4,836.75
II Other Income	2.38	4.26	14.42	45.27
III Total Income (I+II)	1,169.35	1,105.93	1,248.95	4,882.02
IV EXPENSES				
Cost of materials consumed	192.01	280.70	179.63	913.85
Purchases of Stock-in-Trade	211.83	552.33	363.99	1,700.86
Changes in inventories of finished goods,	369.06	(308.52)	173.26	(103.38)
Stock-in -Trade and work-in-progress				-
Employee benefits expense	148.40	184.72	147.27	685.15
Finance costs	7.15	10.29	13.73	43.48
Depreciation and amortization expense	13.74	13.83	13.60	55.22
Other expenses	221.21	364.58	330.60	1,494.71
Total expenses (IV)	1,163.39	1,097.93	1,222.08	4,789.89
V Profit/(loss) before exceptional items and tax (I- IV)	5.96	8.00	26.87	92.13
VI Exceptional Items			-	0.23
VII Profit/(loss) before tax (V-VI)	5.96	8.00	26.87	91.90
VIII Tax expense:				
(1) Current tax	2.00	(9.07)	6.98	12.69
(2) Deferred tax	0.16	0.33	3.70	7.18
Short / ( Excess ) Tax Provision		-	(14.80)	-
IX Profit (Loss) for the period from continuing operations (VII-VIII)	3.80	16.74	30.99	72.03
X Profit/(loss) for the period (IX+XII)	3.80	16.74	30.99	72.03
XI Other Comprehensive Income				
a. Remeasurement gains/(losses) on post employment defined benefit plans		(0.76)		(0.76)
b. Fair value changes of investments	14.68	(35.51)	6.14	(30.34)
(ii) Income tax relating to items that will not be reclassified to profit or loss	(1.52)	3.89	(0.63)	3.85
B (i) Items that will be reclassified to profit or loss	-		-	
(ii) Income tax relating to items that will be reclassified to profit or loss				
XII Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income	16.96	(15.64)	36.50	44.78
XIV Paid Up Equity Capital ( Face Value of Rs 10/- Per share )	708.10	708.10	708.10	708.10
XVI Earnings per equity share (for continuing operation):				
(1) Basic	0.05	0.24	0.44	1.02
(2) Diluted	0.05	0.24	0.44	1.02

Place :- Mumbai  
Date :- 14/09/2020



For Sandu Pharmaceuticals Ltd

Umesh Sandu  
Managing Director  
DIN :- 01132141



1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 14<sup>th</sup> September, 2020. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. Due to nationwide Lockdown imposed due to COVID 19 Pandemic our factory was closed from 23rd March 2020 till 14th April 2020 and all the Production activity was suspended. The operations resumed after 14th April 2020, with requisite approvals of concerned authorities and gradually improved in later part of the quarter .The Company has taken into account the impact of COVID 19 in preparation of the standalone financials statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable value of financial & non-financial assets and impact on revenues. The impact of COVID 19 on the standalone financial statements may differ from that estimated as at the date of approval of these standalone financial statements.
4. The Figures for the quarter ended 31 st March, 2020 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.
6. The Above results are reviewed and recommended by the audit committee and approved by Board of Directors at the meeting held on 14<sup>th</sup> August ,2020 and there are no qualification in the audit report for the quarter ended , 30<sup>th</sup> June , 2020.

Date: - 14/09/2020



For Sandu Pharmaceuticals Ltd

  
Umesh Sandu  
Managing Director  
DIN :- 01132141





**Dileep & Prithvi**  
CHARTERED ACCOUNTANTS

**"LIMITED REVIEW" REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER  
ENDED ON 30th JUNE, 2020**


To,

**The Board of Directors,  
Sandu Pharmaceuticals Limited,**  
Plot No. 25, 26, 29 & 30,  
Pilerne Industrial Estate, Marra,  
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter ended on 30<sup>th</sup> June, 2020, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Dileep & Prithvi**  
Chartered Accountants  
Firm Registration Number: 122290W

  
**Himmat Mali**  
(Partner)

Membership Number: 183378  
UDIN- 20183378AAAABA9175



**HEAD OFFICE :**

4-A, 3rd Floor, Dahanukar Bldg., 480, Kalbadevi Road,  
Mumbai - 400 002. • Tel.: +91-22-22071185 / 40031184  
E-mail : contact@dileepprithvi.com

**BRANCH OFFICE :**

601, Sunshine Building T-39, Opp. Mercedes Auto Hangar,  
Lokhandwala Complex Road, Shastri Nagar, Andheri (W),  
Mumbai - 400 053. • E-mail : prithvi@dileepprithvi.com

**BRANCH OFFICE :**

Office No. 1003-C, 1st Floor, World Trade Centre,  
Near Udhana Darwaja, Ring Road, Surat - 395002. (Gujarat).  
Cell : +91 77679 88047 • E-mail : nikhil@dileepprithvi.co

Place: Mumbai

Date: 14<sup>th</sup> September, 2020